Despite the limited efficacy demonstrated for the mTOR inhibitor everolimus (Ullrich et al., 2021, 2020), a phase 2 selumetinib clinical trial in NF1 patients with grade 1 pilocytic astrocytomas reported significant tumor shrinkage (Fangusaro et al., 2019), supporting the notion that MEK inhibition may more effectively target neoplastic NF1-OPG tumor cells. The gene discussed is NF1; the disease is neurofibromatosis type 1.